Myasthenia Gravis Lecture Flashcards

Definition and Pathophysiology of Myasthenia Gravis

  • Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.

  • The name is derived from Latin and Greek origins, fundamentally meaning "grave muscle weakness."

  • The disorder occurs at the neuron junction and specifically interferes with the transmission of Acetylcholine (ACHACH).

  • The primary anatomic alteration involves an interference with the transmission of ACHACH between the axonal terminal and the receptor sites of voluntary muscles.

  • Pathophysiologic mechanisms involving IgG antibodies:

    • The body produces its own antibodies (specifically AChACh receptor antibodies) that block nerve impulse transmissions at the neuromuscular junction.
    • These antibodies disrupt chemical transmission by blocking AChACh from the receptor sites of the muscular cell.
    • Antibodies may accelerate the breakdown of AChACh.
    • Antibodies can destroy the receptor sites entirely.
  • Secondary anatomic alterations of the lungs (associated with improperly managed ventilatory failure):

    • Mucous accumulation.
    • Airway obstruction.
    • Alveolar consolidation.
    • Atelectasis.

Etiology and Epidemiology

  • Prevalence and Demographics:

    • In the United States, there are approximately 2020 people with myasthenia gravis for every 100,000100,000 people.
    • Young women: Most common in those aged 1515 to 3535, usually occurring under the age of 4040.
    • Older men: Most common in those aged 4040 to 7070, usually occurring over the age of 6060.
  • Provocative factors that often trigger clinical manifestations:

    • Emotional upset.
    • Physical stress.
    • Exposure to extreme changes in temperature.
    • Febrile illness.
    • Pregnancy.

Clinical History and External Symptoms

  • The hallmark of myasthenia gravis is chronic muscle fatigue.

  • Key characteristics of muscle weakness:

    • Weakness increases with activity.
    • Weakness improves significantly after periods of rest.
  • Symptomatic manifestations:

    • Facial muscle weakness.
    • Ptosis: Drooping of one or both eyelids.
    • Diplopia: Double vision.
    • Dysphagia: Difficulty swallowing.
    • Dysarthria: Difficulty speaking.
    • Difficulty chewing.
    • Unstable gait.
    • Weakness in the arms, hands, fingers, legs, and neck, typically brought on by repetitive motions.
  • Progression of muscle involvement:

    • Muscles controlling the eyes, eyelids, face, and throat are especially susceptible and are usually the first to be affected.
    • Respiratory muscles of the diaphragm and chest wall can become weak, severely impairing ventilation.
    • Impairment in deep breathing and coughing predisposes the patient to excessive bronchial secretions, pneumonia, and atelectasis.

Diagnostic Procedures

  • Clinical History and Diagnosis: Based on local weakness and decreased strength throughout the day.

  • Neurologic Examination.

  • Electromyography.

  • Blood Analysis: Specifically looking for ACHACH receptor antibodies.

  • Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).

  • Ice Pack Test: Used for patients with ptosis. An ice pack is applied to the droopy eye for 55 minutes; improvement in ptosis following the application is indicative of MG.

  • Edrophonium (Tensilon Challenge) Test: Used to both diagnose and monitor therapy. Edrophonium (Tensilon) is administered to observe its effect on muscle strength (measured via VTV_T, VCVC, and NIFNIF).

  • Differential Outcomes of Tensilon Challenge:

    • Improvement: If symptoms improve, it is referred to as a Myasthenic Crisis, indicating a need for more anticholinesterase drug therapy.
    • Worsening: If symptoms worsen, it is referred to as a Cholinergic Crisis, indicating that too much anticholinesterase medication has been given.
    • Atropine: Administered to reverse the effects of Tensilon and relieve symptoms of a cholinergic crisis.

Physical Examination and Cardiopulmonary Manifestations

  • Physical Examination Findings:

    • Respiratory Rate: Varies with the degree of muscle paralysis; severe cases may exhibit apnea.
    • Cyanosis.
    • Diminished breath sounds.
    • General weakness in a "mind to ground" distribution.
  • Chest Assessment Findings:

    • Diminished breath sounds.
    • Crackles and rhonchi.
  • Pulmonary Function Test (PFT) Findings (Moderate to Severe Restrictive Pathophysiology):

    • Tidal Volume (VTV_T): Decreased.
    • Inspiratory Reserve Volume (IRVIRV): Decreased.
    • Expiratory Reserve Volume (ERVERV): Decreased.
    • Residual Volume (RVRV): Decreased.
    • Vital Capacity (VCVC): Decreased.
    • Inspiratory Capacity (ICIC): Decreased.
    • Functional Residual Capacity (FRCFRC): Decreased.
    • Total Lung Capacity (TLCTLC): Decreased.
    • RV/TLCRV/TLC ratio: Normal.
    • Negative Inspiratory Force (NIFNIF) / MIP: Decreased.
  • Arterial Blood Gases (Moderate to Severe MG/Acute Ventilatory Failure w/ Hypoxemia):

    • pHpH: Decreased.
    • PaCO2PaCO_2: Increased.
    • HCO3HCO_3: Slightly increased.
    • PaO2PaO_2: Decreased.
  • Radiologic Findings on Chest Radiograph:

    • Normal in early stages.
    • Increased opacity when atelectasis is present.

General Management and Therapeutic Protocols

  • Monitoring: Frequent measurements of Vital Capacity (VCVC), Negative Inspiratory Force (NIFNIF), blood pressure, pulse oxygenation saturation, and arterial blood gases.

  • Primary Medications:

    • Cholinesterase inhibitors (anticholinesterase therapy): Neostigmine (Prostigmin) and Pyridostigmine (Mestinon, Regonol). First attempted usage of these was June 2nd, 1935.
    • Immunosuppressants.
    • Adrenocorticotropic hormone (ACTH) therapy.
  • Surgical and Advanced Interventions:

    • Thymectomy: Removal of the thymus gland.
    • Plasmapheresis.
  • Respiratory Care Treatment Protocols:

    • Oxygen Therapy: Increase FiO2FiO_2 up to 60%60\%; if still hypoxemic, add CPAP/PEEP.
    • Hyperinflation Therapy: e.g., IPPB for the treatment of atelectasis.
    • Bronchopulmonary Hygiene Protocol: To treat mucus accumulation and airway obstruction.
    • Lung Expansion Therapy Protocol.
    • Mechanical Ventilation Protocol: Initiated when clinical data demonstrate impending or acute ventilatory failure.
  • Clinical Indicators for Mechanical Ventilation (Acute Ventilatory Failure):

    • VC<20 mL/kgVC < 20\,mL/kg.
    • NIF<−30 cm H2ONIF < -30\,cm\,H_2O.
    • pH<7.35pH < 7.35 or PaCO2>45 mm HgPaCO_2 > 45\,mm\,Hg.

Questions & Discussion

  • Question: The fundamental anatomic alteration found with myasthenia gravis is a problem with:

    • Response: B. voluntary muscle acetylcholine (ACHACH) transmission.
  • Question: All of the following are possible ways that the IgG antibodies found in a myasthenia gravis patient lead to muscle weakness, EXCEPT:

    • Answer: D. breakdown the nerves’ myelin sheath (Note: antibodies block AChACh, breakdown AChACh faster, or destroy AChACh receptor sites).
  • Question: The major pathologic or structural changes of the lungs associated with ventilatory failure accompanying myasthenia gravis include:

    • Answer: A. 1 (alveolar consolidation) and 4 (atelectasis).
  • Question: Commonly encountered chest assessment findings in a patient with myasthenia gravis include:

    • Answer: B. 1 (diminished breath sounds) and 3 (crackles and rhonchi).
  • Question: The most important thing to assess in the myasthenia gravis patient to determine acute ventilatory failure is:

    • Options: Peak flow, arterial blood pH, negative inspiratory force, tidal volume measurement.
    • Reference data: Negative inspiratory force (NIFNIF) and Vital Capacity (VCVC) are critical monitoring tools.